Scarica l'app Stockscreener
2.13
2.91%
-0.10
Precedente Chiudi:
$2.23
Aprire:
$2.27
Volume 24 ore:
82,220
Relative Volume:
0.64
Capitalizzazione di mercato:
$56.49M
Reddito:
-
Utile/perdita netta:
$-19.77M
Rapporto P/E:
-1.3567
EPS:
-1.57
Flusso di cassa netto:
$-13.07M
1 W Prestazione:
+1.64%
1M Prestazione:
-18.61%
6M Prestazione:
-40.19%
1 anno Prestazione:
+88.26%
Intervallo 1D:
$2.12
$2.27
Intervallo di 1 settimana:
$1.80
$2.4849
Portata 52W:
$0.82
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Nome
MAIA Biotechnology Inc
Settore
Industria
Telefono
312 416 8592
Indirizzo
444 West Lake Street, Suite 1700, Chicago
Confronta MAIA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| MAIA | 2.12 | 56.49M | 0 | -19.77M | -13.07M | -1.57 |
| VRTX | 449.85 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.37 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 600.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.07 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
MAIA Biotechnology Inc Borsa (MAIA) Ultime notizie
Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings - Defense World
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MAIA Biotechnology Inc (MAIA): A New Perspective - Stocks Register
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
MAIAMAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - BioSpace
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Canada
Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock - MarketBeat
Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechno - GuruFocus.com
Director Ramiro Guerrero Acquires 88,534 Shares of MAIA Biotechn - GuruFocus.com
Maia Biotechnology director Steven Chaouki buys $55,553 in shares By Investing.com - Investing.com Australia
Maia Biotechnology director Steven Chaouki buys $55,553 in shares - Investing.com
Maia Biotechnology director Luput acquires shares worth $55,553 By Investing.com - Investing.com Nigeria
Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com
Cosmo Metals Secures $500,000 for Strategic Expansion - MSN
Antipa Minerals Expands Share Offering on ASX - MSN
WAM Alternative Assets Expands ASX Securities Offering - MSN
Argent BioPharma Issues New Shares Amidst Strategic Growth - MSN
MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4%Here's What Happened - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% – Time to Sell? - Defense World
Alterity Therapeutics Prepares for 2024 Annual General Meeting - MSN
Li Bang International announces pricing of initial public offering - MSN
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - BioSpace
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 1.1% - MarketBeat
BioAge, BKV shares end their first trading day flat after earlier gains - MSN
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO - MSN
Healthcare Stock Performance - Yahoo Finance
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE) - Defense World
Promising signs for MAIA’s telomere-targeting treatment - The Pharma Letter
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8% - Defense World
THIO Combo Yields Survival Benefit in Advanced NSCLC - AJMC.com Managed Markets Network
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CAE - PR Newswire
Summit Therapeutics jumps 4%, raises $235M - MSN
MAIA Biotechnology - The Pharma Letter
MAIA Biotechnology Reports Promising Interim Results in Lung Cancer Treatment Study - Vancity Buzz
MAIA Biotechnology Inc’s latest rating changes from various analysts - Knox Daily
MAIA reports survival benefit in advanced lung cancer trial - Investing.com
MAIA Biotech releases Phase II results for THIO - The Pharma Letter
MAIA reports survival benefit in advanced lung cancer trial By Investing.com - Investing.com Australia
MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - StockTitan
MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.9% - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.9% - Defense World
MAIA Biotechnology Inc Azioni (MAIA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Capitalizzazione:
|
Volume (24 ore):